403 related articles for article (PubMed ID: 27909037)
1. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial.
Zhu X; Ju X; Cao F; Fang F; Qing S; Shen Y; Jia Z; Cao Y; Zhang H
BMJ Open; 2016 Dec; 6(12):e013220. PubMed ID: 27909037
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
[TBL] [Abstract][Full Text] [Related]
4. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
Yamaue H; Satoi S; Kanbe T; Miyazawa M; Tani M; Kawai M; Hirono S; Okada K; Yanagimoto H; Kwon AH; Mukouyama T; Tsunoda H; Chijiiwa K; Ohuchida J; Kato J; Ueda K; Yamaguchi T; Egawa S; Hayashi K; Shirasaka T
Cancer Chemother Pharmacol; 2014 Jan; 73(1):97-102. PubMed ID: 24146260
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
[TBL] [Abstract][Full Text] [Related]
9. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
16. S-1 in the treatment of pancreatic cancer.
Sudo K; Nakamura K; Yamaguchi T
World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
[TBL] [Abstract][Full Text] [Related]
17. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
Wang X; Zhao DB; Yang L; Chi Y; Tang Y; Li N; Wang SL; Song YW; Liu YP; Liu WY; Ren H; Zhang T; Wang JY; Chen XS; Fang H; Wang WH; Li YX; Jin J
Br J Cancer; 2018 Feb; 118(3):338-343. PubMed ID: 29235569
[TBL] [Abstract][Full Text] [Related]
18. S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol.
Liu F; Wang C; Hu T; Wang W
Medicine (Baltimore); 2018 Apr; 97(15):e0397. PubMed ID: 29642202
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S
Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Shirai Y; Nakagawa A; Kawakami H; Uno T; Ito H; Saisho H
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):219-24. PubMed ID: 17189072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
